SLC5A2 and diabetes mellitus: Since SGLT2 inhibitors have positive effects on CV risk factors such as reducing blood pressure, body weight in addition to their HbA1c lowering effect [17, 18] this class of drugs may be of use for intervention in early stages of diabetes/prediabetes [18].